ACW successfully completes $16.8m Placement and SPP
Filed with ASX · · 3 pages · English
Sydney, 27 February 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that its share purchase plan (SPP) is now complete, with $4.8 million raised from existing shareholders1. This brings total funding from this capital raising round to $16.8 million, when combined with the $12.0 million in placement funding (Placement) announced on 2 February 2026. The SPP was offer
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
- Actinogen HY2025 financial report and Appendix 4D
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW secures funding beyond XanaMIA AD trial final results
Later from Actinogen Medical
- ACW XanaMIA Alzheimers open label trial commences
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen receives positive scientific advice from EMA
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical